Next Generation Sequencing Market By PRODUCT (Consumables, Platforms, Services), By APPLICATION (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized medicine, Agriculture and animal research, Others), By TECHNOLOGY (Sequencing By synthes

Next Generation Sequencing Market By PRODUCT (Consumables, Platforms, Services), By APPLICATION (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized medicine, Agriculture and animal research, Others), By TECHNOLOGY (Sequencing By synthesis (SBS), Ion semiconductor sequencing (IOS), Sequencing By Ligation (SBL), Pyrosequencing, Single-molecule-real-time sequencing (SMRT), Others), By END USER (Academic and clinical research centers, Pharmaceutical and biotechnology companies, Hospitals and clinics, Others): Global Opportunity Analysis and Industry Forecast, 2024-2035

The next generation sequencing market was valued at $ 13 billion in 2023 and is estimated to reach $97.8 billion by 2035, exhibiting a CAGR of 18.3% from 2024 to 2035. Next generation sequencing (NGS) is a novel procedure for sequencing genomes at low costs and high speed with improved efficiency. NGS, also known as deep sequencing and parallel sequencing, is a technology that has revolutionized molecular biology and genomics research. It is a high throughput, non-Sanger based sequencing method. Next generation sequencing has made sequencing of genomes very rapid and cost-effective. Through this method, billions of DNA strands can be sequenced efficiently. Next generation sequencing has made it possible to conveniently sequence whole genomes and analyze various DNA-protein interactions. This technique allows the researcher to focus, study, and interpret deep sequence target regions. Next generation sequencing can be utilized through varied interventions such as oncology, biomarker studies, drug discovery, understanding reproductive health, and personalized genomics.The major factors driving the growth of the NGS market include rise in technological advancements, rise in the number of collaborations & partnerships to promote the use of NGS in hospitals & research centers, and increase in genome mapping programs throughout the world. For instance, in March 2023, Qiagen N.V. N.V. announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM that will bring together its QIAseq technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform. Similarly, in June 2021, Labcorp, a global leading life science company, and OmniSeq, a molecular diagnostic of Rosewell Park Comprehensive Cancer Center, together announced the launch of OmniSeq INSIGHT, which is a next generation sequencing platform to advance the precision oncology and improve patient outcome.The next generation sequencing market is segmented into product, application, technology, end user, and region. By product, the market is classified into consumables, platforms, and services. On the basis of application, the market is fragmented into biomarkers & cancer, diagnostics, reproductive health, personalized medicine, agriculture & animal research, and other applications. On the basis of technology, the market is segmented into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing, and other technologies. By end user, the market is divided into academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics.  Region-wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, North Africa, Middle East & Africa).The key players that operate in the next generation sequencing market are Agilent Technologies, Inc., BGI Group, F. Hoffmann-La Roche AG, Illumina Inc, Precigen Inc., (Intrexon Bioinformatics Germany GmbH), Pacific Biosciences of California, Inc., PerkinElmer, Inc., PierianDx Inc., Qiend usern N.V., and Thermo Fisher Scientific Inc. The key players have adopted product launch, product development, collaboration, partnership, and product approval as the key strategies to strengthen their foothold in the competitive market.

Key Benefits for StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation sequencing market analysis from 2023 to 2035 to identify the prevailing next generation sequencing market opportunities.The market research is offered along with information related to key drivers, restraints, and opportunities.Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.In-depth analysis of the next generation sequencing market segmentation assists to determine the prevailing market opportunities.Major countries in each region are mapped according to their revenue contribution to the global market.Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.The report includes the analysis of the regional as well as global next generation sequencing market trends, key players, market segments, application areas, and market growth strategies.

Regulatory Guidelines
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By TECHNOLOGY

Sequencing by synthesis (SBS)
Ion semiconductor sequencing (IOS)
Sequencing by Ligation (SBL)
Pyrosequencing
Single-molecule-real-time sequencing (SMRT)
Others

By END USER

Academic and clinical research centers
Pharmaceutical and biotechnology companies
Hospitals and clinics
Others

By PRODUCT

Consumables
Type
Sample Preparation Consumables

Type
Other Consumables
Platforms
Type
MiSeq
Ion Torrent
SOLiD
Pacbio Rs II and Sequel System
Others
Services
Type
Sequencing Services◦
Type
Data Management Services

Type

By APPLICATION

Diagnostics
Biomarkers and Cancer
Reproductive Health
Personalized medicine
Agriculture and animal research
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ILLUMINA INC.
F. HOFFMANN-LA ROCHE AG
Qiagen N.V
abgi group
PerkinElmer, Inc
Agilent Technologies, Inc.
Pacific Biosciences of California
Thermo Fisher Scientific Inc.
PRECIGEN INC